ATE253073T1 - Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase - Google Patents

Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase

Info

Publication number
ATE253073T1
ATE253073T1 AT98909031T AT98909031T ATE253073T1 AT E253073 T1 ATE253073 T1 AT E253073T1 AT 98909031 T AT98909031 T AT 98909031T AT 98909031 T AT98909031 T AT 98909031T AT E253073 T1 ATE253073 T1 AT E253073T1
Authority
AT
Austria
Prior art keywords
fructose
bisphosphatase
new benzimidazole
benzimidazole inhibitors
inhibitors
Prior art date
Application number
AT98909031T
Other languages
English (en)
Inventor
Srinivas Rao Kasibhatla
K Raja Reddy
Mark D Erion
Qun Dang
Gerard R Scarlato
M Rami Reddy
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Application granted granted Critical
Publication of ATE253073T1 publication Critical patent/ATE253073T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98909031T 1997-03-07 1998-03-06 Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase ATE253073T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4062797P 1997-03-07 1997-03-07
PCT/US1998/004498 WO1998039343A1 (en) 1997-03-07 1998-03-06 Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase

Publications (1)

Publication Number Publication Date
ATE253073T1 true ATE253073T1 (de) 2003-11-15

Family

ID=21912034

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98909031T ATE253073T1 (de) 1997-03-07 1998-03-06 Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase

Country Status (11)

Country Link
US (2) US6110903A (de)
EP (1) EP0970095B1 (de)
JP (1) JP2001515482A (de)
AT (1) ATE253073T1 (de)
AU (1) AU6691498A (de)
DE (1) DE69819311T2 (de)
DK (1) DK0970095T3 (de)
ES (1) ES2210728T3 (de)
PT (1) PT970095E (de)
WO (1) WO1998039343A1 (de)
ZA (1) ZA981936B (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981936B (en) * 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1999045016A2 (en) 1998-03-06 1999-09-10 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE69910045T2 (de) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
ATE300288T1 (de) * 1998-12-24 2005-08-15 Metabasis Therapeutics Inc Zusammensetzung enthaltend insulin- sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
EP1165570B9 (de) 1999-03-05 2007-02-21 Metabasis Therapeutics, Inc. Neue phosphor enthaltende medikamentenvorläuferverbindungen
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2001018013A1 (en) * 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
AU2006202624B2 (en) * 1999-12-22 2008-08-14 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
AU784370B2 (en) * 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
ES2275654T5 (es) 2000-01-21 2012-06-07 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
MXPA02008722A (es) 2000-03-08 2004-05-05 Metabasis Therapeutics Inc Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0301830A3 (en) * 2000-07-06 2007-10-29 Metabasis Therapeutics Inc Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
JP4332496B2 (ja) * 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびｐｍｐａ環生成合成
JP4476811B2 (ja) 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
JP4689274B2 (ja) * 2002-10-31 2011-05-25 リガンド・ファーマシューティカルズ・インコーポレイテッド 新規なシタラビン・モノホスフェートプロドラッグ
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
MXPA06014013A (es) * 2004-06-08 2007-03-15 Metabasis Therapeutics Inc Sintesis mediada por acidos de lewis de esteres ciclicos.
KR20070053764A (ko) * 2004-08-18 2007-05-25 메타베이시스 테라퓨틱스, 인크. 프럭토스 1,6-비스포스파타제의 신규한 티아졸 억제제들
WO2006110683A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
EP1752450A1 (de) 2005-08-01 2007-02-14 Merck Sante Imidazolderivate als Fruktose-1,6-biphosphataseinhibitoren und pharmazeutische Zusammensetzungen diese enthaltend
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
EP1966157B1 (de) 2005-11-15 2010-03-24 Abbott Laboratories Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE553104T1 (de) 2006-05-02 2012-04-15 Abbott Lab Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
US8466096B2 (en) * 2007-04-26 2013-06-18 Afton Chemical Corporation 1,3,2-dioxaphosphorinane, 2-sulfide derivatives for use as anti-wear additives in lubricant compositions
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
EP2058308A1 (de) 2007-11-12 2009-05-13 Merck Sante Benzimidazoldihydrothiadiazinonderivate als Fructose-1,6-biphosphatase-Hemmer und diese enthaltende pharmazeutische Zusammensetzungen.
HRP20141038T2 (hr) 2008-04-28 2015-07-03 Janssen Pharmaceutica N.V. Benzoimidazoli kao inhibitori prolil hidroksilaze
AU2009296820B2 (en) 2008-09-26 2014-03-20 Merck Sharp & Dohme Llc Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
DK3366686T3 (da) 2009-03-20 2020-11-23 Metabasis Therapeutics Inc Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2464228B1 (de) 2009-08-13 2017-12-06 Merck Sharp & Dohme Corp. Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und behandlungsverfahren damit
WO2011028455A1 (en) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
HRP20140114T1 (hr) 2010-02-03 2014-03-14 Takeda Pharmaceutical Company Limited Inhibitori kinaze 1 koji reguliraju signal apoptoze
US8853212B2 (en) 2010-02-22 2014-10-07 Merck Sharp & Dohme Corp Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP2571876B1 (de) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituierte siebenteilige heterozyklische verbindungen als dipeptidyl-peptidase-iv-hemmer zur behandlung von diabetes
EP2605658B1 (de) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinonverbindungen
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
PH12013501686A1 (en) 2011-02-25 2017-10-25 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AU2012240122B2 (en) 2011-04-08 2016-08-25 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
CA2837517A1 (en) 2011-06-02 2012-12-06 Intervet International B.V. Imidazole derivatives
CA2838079A1 (en) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
EP2760855B1 (de) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und ihre verwendung bei der behandlung von typ-2 diabetes
EP2771000B1 (de) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituierte piperidinylverbindungen als gpr119-agonisten
MX368157B (es) 2011-10-25 2019-09-20 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
WO2013068328A1 (en) 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013068439A1 (en) 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
JP6101279B2 (ja) 2011-11-15 2017-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｇｐｒ１１９アゴニストとして有用な置換シクロプロピル化合物
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN104411710A (zh) 2012-04-16 2015-03-11 卡内克制药公司 作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
WO2014031445A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
WO2014031468A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014031441A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
EP2888008B1 (de) 2012-08-22 2018-12-26 Merck Sharp & Dohme Corp. Neuartige azabenzimidazol-tetrahydrofuranderivate
RU2015109706A (ru) 2012-08-22 2016-10-10 Мерк Шарп И Доум Корп. Новые производные азабензимидазол гексагидрофуро[3, 2-в]фурана
WO2014099578A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2747973T3 (es) 2013-11-15 2020-03-12 Merck Sharp & Dohme Compuestos tricíclicos antidiabéticos
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
WO2016022448A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CA3093383A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
EP3078378B1 (de) 2015-04-08 2020-06-24 Vaiomer Verwendung von faktor-xa-inhibitoren zur regulierung von glykämie
EP3303342B1 (de) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Als lösliche guanylat-cyclase-aktivatoren geeignete imidazopyrazinylderivate
EP3310782B1 (de) 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Als lösliche guanylat-cyclase-aktivatoren geeignete imidazopyrazinylderivate
EP3359191A4 (de) 2015-10-05 2019-05-29 Merck Sharp & Dohme Corp. Antikörper-peptid-konjugate mit agonistenaktivität an rezeptoren von glucagon als auch glukagon-like peptid-1
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
WO2018034918A1 (en) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
EP3496715B1 (de) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Zur veränderung der konzentrationen von gallensäuren nützliche verbindungen zur behandlung von diabetes und kardiometabolischen erkrankungen
EP3515891B1 (de) 2016-09-20 2023-03-08 Merck Sharp & Dohme LLC Substituierte 1-methyl-1,2,3,4-tetrahydroisochinolin-moleküle als allosterische pcsk9-bindemittel
AU2017360939B2 (en) 2016-11-18 2022-03-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
BR112019009731A2 (pt) 2016-11-18 2019-08-13 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento
WO2018107415A1 (en) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds useful as gpr120 agonists
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
WO2020205688A1 (en) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
EP4021919A1 (de) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9-antagonist-verbindungen
EP3842060A1 (de) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Geheftete lactam-co-agonisten der glucagon- und glp-1-rezeptoren
EP3842449A1 (de) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Geklammerte olefin-co-agonisten der glucagon- und glp-1-rezeptoren
EP3842061A1 (de) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Geheftete triazol-co-agonisten der glucagon- und glp-1-rezeptoren
EP4153596A4 (de) 2020-05-18 2024-08-14 Merck Sharp & Dohme LLC Neue diacylglycerid-o-acyltransferase-2-inhibitoren
MX2023003842A (es) 2020-10-08 2023-04-14 Merck Sharp & Dohme Llc Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2.
KR20230079427A (ko) 2020-10-08 2023-06-07 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조
JP2024532129A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｃｓｋ９活性に関連する状態を治療するための化合物
GEAP202516706A (en) 2022-06-15 2025-07-10 Merck Sharp & Dohme Llc Cyclic peptides for trapping interleukin-1 beta
WO2024118858A1 (en) 2022-12-02 2024-06-06 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
WO2025106386A1 (en) 2023-11-14 2025-05-22 Merck Sharp & Dohme Llc A cyclic peptide for trapping interleukin-1 beta
WO2025128805A1 (en) 2023-12-15 2025-06-19 Merck Sharp & Dohme Llc A cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000305A (en) * 1972-09-27 1976-12-28 Imperial Chemical Industries Limited 15-, 16- AND 17-Indolyl or indolinyl nor prostanoic acid derivatives
GB1428137A (en) * 1972-09-27 1976-03-17 Ici Ltd Prostanoic acid derivatives
DE2855659A1 (de) * 1978-12-22 1980-07-03 Bayer Ag Benzimidazolyl-2-alkan-phosphonsaeuren
GR81744B (de) * 1983-01-28 1984-12-12 Schering Corp
ATE72816T1 (de) * 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
US4943629A (en) * 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
DE69014562T2 (de) * 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2658511B1 (fr) * 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
TW222637B (de) * 1991-12-12 1994-04-21 Hoechst Ag
US5302586A (en) * 1991-12-19 1994-04-12 G. D. Searle & Co. Phosphonomethyl-imidazo[1,2-a]pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury
KR0185225B1 (ko) * 1992-05-21 1999-05-15 오오쓰까 아끼히꼬 포스폰산 디에스테르 유도체
JP2789134B2 (ja) * 1992-09-28 1998-08-20 ファイザー・インク． 糖尿病の合併症を制御する置換ピリミジン類
DE59309360D1 (de) * 1992-12-02 1999-03-18 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
TW260664B (de) * 1993-02-15 1995-10-21 Otsuka Pharma Factory Inc
US5719303A (en) * 1993-03-08 1998-02-17 Eisai Co., Ltd. Phosphonic acid derivatives
JPH06298779A (ja) * 1993-04-15 1994-10-25 Hoechst Japan Ltd ヘテロ環イミノビスメチレンビスホスホン酸誘導体
ZA981936B (en) * 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
KR20010033811A (ko) * 1997-12-31 2001-04-25 토마스 안 빅토리아 2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법

Also Published As

Publication number Publication date
US6399782B1 (en) 2002-06-04
JP2001515482A (ja) 2001-09-18
EP0970095A1 (de) 2000-01-12
ES2210728T3 (es) 2004-07-01
AU6691498A (en) 1998-09-22
DE69819311T2 (de) 2004-07-29
DE69819311D1 (de) 2003-12-04
EP0970095B1 (de) 2003-10-29
US6110903A (en) 2000-08-29
WO1998039343A1 (en) 1998-09-11
ZA981936B (en) 1999-09-06
DK0970095T3 (da) 2004-03-08
PT970095E (pt) 2004-03-31

Similar Documents

Publication Publication Date Title
DE69819311D1 (de) Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
MX9700557A (es) Dihidrobenzofuranos.
ID24372A (id) SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
PT892780E (pt) Analogos de m-amidino fenilo como inibidores do factor xa
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
DE59310137D1 (de) Verwendung von substituierten Benzimidazolen zur Bekämpfung parasitärer Protozoen
DE69813616D1 (de) Cyclohexencarboxylate als inhibitoren der neuraminidase
ATE243993T1 (de) Verwendung von 5ht3 antagonisten zum fördern der darmspülung
EA200000251A1 (ru) Производные резорцинола
IS5272A (is) Nýtt form S-ómeprasóls
EA199700061A1 (ru) Способ получения силденафила
TR199900239T2 (de)
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
BR9711586A (pt) Compostos e uso dos mesmo
NO20001979L (no) Anvendelse av inhibitorer av renin-angiotensin-systemet
BR0007864A (pt) Composto, e, uso de um composto
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
ATE497786T1 (de) Zusammensetzungen und kits zur erhöhung der abgabe von therapeutischen mitteln an zellen
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
DK0722722T3 (da) Anvendelse af en antagonist for P-substans til behandling af kutan rødme af neurogen oprindelse
PT696194E (pt) Utilizacao de derivados de indole como antagonistas de 5ht1
DE69834271D1 (de) Steroid-3-o-sulfamat-derivate als estronsulfatase-hemmer
IS2143B (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
ID22060A (id) Senyawa-senyawa 2-imidazolinilaminobenzoksazol berguna sebagai agonis adrenoseptor
FI952458L (fi) Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-antagonisteina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0970095

Country of ref document: EP

REN Ceased due to non-payment of the annual fee